Turning Point Therapeutics, Inc.
Clinical trials sponsored by Turning Point Therapeutics, Inc., explained in plain language.
-
New drug targets genetic flaws in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib (TPX-0005) in people with advanced solid tumors that have certain genetic changes (ALK, ROS1, or NTRK). The goal is to see if the drug is safe and can shrink tumors. About 500 adults will take part, first to find the best dose, the…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
New hope for kids with rare cancers: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced cancers that have specific genetic changes (ALK, ROS1, or NTRK). The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 75 participan…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 12:01 UTC